Abstract
Derived from the myeloid lineage, granulocytes, including basophils, eosinophils, and neutrophils, along with mast cells, play important, often disparate, roles across the allergic disease spectrum. While these cells and their mediators are commonly associated with allergic inflammation, they also exhibit several functions either promoting or restricting tumor growth. In this Position Paper we discuss common granulocyte and mast cell features relating to immunomodulatory functions in allergy and in cancer. We highlight key mechanisms which may inform cancer treatment and propose pertinent areas for future research. We suggest areas where understanding the communication between granulocytes, mast cells, and the tumor microenvironment, will be crucial for identifying immune mechanisms that may be harnessed to counteract tumor development. For example, a comprehensive understanding of allergic and immune factors driving distinct neutrophil states and those mechanisms that link mast cells with immunotherapy resistance, might enable targeted manipulation of specific subpopulations, leading to precision immunotherapy in cancer. We recommend specific areas of investigation in AllergoOncology and knowledge exchange across disease contexts to uncover pertinent reciprocal functions in allergy and cancer and allow therapeutic manipulation of these powerful cell populations. These will help address the unmet needs in stratifying and managing patients with allergic diseases and cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 2319-2345 |
| Number of pages | 27 |
| Journal | Allergy |
| Volume | 79 |
| Issue number | 9 |
| Early online date | 22 Jul 2024 |
| DOIs | |
| Publication status | Published - Sept 2024 |
Bibliographical note
Publisher Copyright:© 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Funding
All authors have read and approved the Position Paper. RB, LdV, AP, EI, EFK, TWJR, FLS, CM and FR declare no conflict of interest. AFS reports grants from Medical Research Council (MR/M008517/1; MC/PC/18052; MR/T032081/1), Food Allergy Research and Education (FARE), the Immune Tolerance Network/National Institute of Allergy and Infectious Diseases (NIAID, NIH), Asthma UK (AUK\u2010BC\u20102015\u201001), BBSRC, Rosetrees Trust and the NIHR through the Biomedical Research Centre (BRC) award to Guy's and St Thomas' NHS Foundation Trust, during the conduct of the study; personal fees from Thermo Scientific, Nestle, Novartis, Allergy Therapeutics, IgGenix and Mabylon, as well as research support from Thermo Fisher Scientific through a collaboration agreement with King's College London. SNK is academic founder and shareholder of Epsilogen Ltd. (formerly IGEM Therapeutics Ltd.) and has received funds from IGEM Therapeutics Ltd/Epsilogen Ltd. HJB is employed through a fund provided by Epsilogen Ltd. SNK and HJB are inventors of patents on antibody technologies. SNK reports grants from the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London (IS\u2010BRC\u20101215\u201020,006), Guy's and St Thomas's Foundation Trust Charity Melanoma Special Fund (573); the British Skin Foundation (006/R/22); Cancer Research UK (C30122/A11527; C30122/A15774); the CRUK City of London Centre Award (C7893/A29290); Breast Cancer Now (147; KCL\u2010BCN\u2010Q3); the Medical Research Council (MR/L023091/1; MR/R015643/1; MR/V049445/1); Innovate UK (51746); SNK is supported by the King's Health Partners Centre for Translational Medicine. JC has been employed through a fund provided by Epsilogen Ltd. CB received honoraria for presentations from Allergy Therapeutics, Bencard, HAL Allergy and SCS. EJJ declares inventorship in patents on allergen immunotherapy formulation with Biomedical International R\u2009+\u2009D, Vienna, Austria, of which she is shareholder. She received honoraria for presentations from Allergy Therapeutics, AllergoPharma, Bencard Allergie, Meda, Menarini, Roxall, Santen, Sanofi, ThermoFisher. UJ has received a hotel accommodation and catering for a lecture and chairing of a workshop organized by ALK Abello. The honorarium went to her institution, the RCB. Her research on molecular allergology is funded by the Federal Ministry of Education and Science, the Federal Ministries of Technology, Economy and Technology, Food and Agriculture (BMEL), the German Research Foundation, and the Kanert Foundation. MP received honoraria for presentations from ThermoFisher Scientific and LETI Pharma SLU. KH has received consultancy or lecture fees from ALK\u2010Abello, Allergopharma, Blueprint, Cogent, KalVista, LEO Pharma, Menarini, Novartis, Pfizer, Sanofi, Takeda, and Thermo Fisher, travel support from Allergopharma and Blueprint and research funding from Thermo Fisher. MC declares American Board of Allergy and Immunology (ABAI): Board of Directors, AAAAI Foundation Research Chair, Editor in Chief of Current Allergy and Asthma Reports, UpToDate: Author, NIH: Systemic Allergic Reactions to SARS\u2010COV\u20102 Vaccination, NIH: Allergy Data and Safety Monitoring Board (DSMB), BluePrint: BLU\u2010285 and BLU\u2010263 Studies PI BWH, Consultant for Daiichi Sankyo, Cogent Biosciences: SUMMIT Trials. This Position Paper was supported by the European Academy for Allergy and Clinical Immunology (EAACI) under the EAACI Task force \u201CGranulocytes (mast cells, basophils, neutrophils eosinophils): understanding their roles in allergy and tumor immunity\u201D within the Working group for AllergoOncology within the Basic Immunology Section (2023). The authors would like to thank EAACI for financial support in the development of this position paper. SNK has projects supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London (IS\u2010BRC\u20101215\u201020006); the Medical Research Council (MR/L023091/1, MR/V049445/1, MR/R015643/1), the Biotechnology and Biological Sciences Research Council (BB/T008709/1); Breast Cancer Now (147; KCL\u2010BCN\u2010Q3); the Cancer Research UK King's Health Partners Centre at King's College London (C604/A25135); The Guy's and St Thomas's Foundation Trust Charity (Melanoma Special Fund, 573); Innovate UK (463087) the British Skin Foundation (006/R/22); Worldwide Cancer Research (24\u20100087); Cancer Research UK (C30122/A11527; C30122/A15774). SNK has projects supported by the King's Health Partners Centre for Translational Medicine. The views expressed are those of the author(s) and not necessarily those of King's Health Partners. UJ has projects funded by the German Research Foundation (DFG) (JA 1007/2\u20133), the Federal Ministry of Education and Science (BMBF) (DZL and INDICATE\u2010FH), and the Federal Ministry of Food and Agriculture (BMEL) (AptaSens). MP is employed by Hospital Cl\u00EDnic de Barcelona, Spain, and has projects funded by Instituto Carlos III (ISCIII) and co\u2010funded by the European Union (PI19/00710 and PI22/01469) and RICORS (RD21/0002/0008) from ISCIII co\u2010founded by the European Union. AP is financially supported by the Action Lions Vaincre le Cancer association and by FNRS\u2010T\u00E9l\u00E9vie (TLV 2023 RESTAGE). CM has a contract Nicolas Monardes Program (RC0004\u20102021) and projects PI18/00288 from ISCIII co\u2010funded by the European Regional Development Fund (ERDF) \u201CUna manera de hacer Europa\u201D \u201CAndaluc\u0131a se mueve con Europa\u201D, and PI21/00346 and RICORS (RD21/0002/0008) from ISCIII co\u2010founded by the European Union. KH has projects supported by the Swiss National Science Foundation (project no. 310030_207705) and by the EU\u2010H2020\u2010MSCA\u2010COFUND EURIdoc programme (project no. 101034170).
| Funders | Funder number |
|---|---|
| Rosetrees Trust | |
| Guy's and St Thomas' NHS Foundation Trust | |
| AllergoOncology | |
| Instituto de Salud Carlos III | |
| Kanert Foundation | |
| King's Health Partners Centre for Translational Medicine | |
| Allergopharma and Blueprint | |
| National Institute for Health and Care Research | |
| Federal Ministry of Education and Science | |
| Federal Ministry of Food and Agriculture | |
| BMEL | |
| Guy's and St Thomas's Foundation Trust Charity Melanoma Special Fund | |
| BBSRC | |
| National Institute of Allergy and Infectious Diseases | |
| Novartis | |
| German Research Foundation | |
| European Academy of Allergy and Clinical Immunology | |
| NIAID | |
| Guy's and St Thomas's Foundation Trust Charity | |
| Food Allergy Research and Education | |
| Federal Ministries of Technology, Economy and Technology, Food and Agriculture | |
| Action LIONS Vaincre le Cancer | |
| Allergy Therapeutics | |
| Immune Tolerance Network | |
| Melanoma Special Fund | 573 |
| DFG | JA 1007/2–3 |
| British Skin Foundation | 006/R/22 |
| King's College London | IS‐BRC‐1215‐20,006 |
| Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung | 101034170, 310030_207705 |
| Cancer Research UK King's Health Partners Centre at King's College London | C604/A25135 |
| BMBF | INDICATE‐FH |
| NIH | AUK‐BC‐2015‐01 |
| European Regional Development Fund | PI21/00346 |
| Innovate UK | 463087, 51746 |
| Biotechnology and Biological Sciences Research Council | BB/T008709/1 |
| RICORS | RD21/0002/0008 |
| Medical Research Council | MR/V049445/1, MC/PC/18052, MR/T032081/1, MR/R015643/1, MR/L023091/1, MR/M008517/1 |
| Breast Cancer Now | KCL‐BCN‐Q3 |
| Cancer Research UK | C7893/A29290, C30122/A11527, C30122/A15774 |
| Worldwide Cancer Research | 24‐0087 |
| FNRS‐Télévie | TLV 2023 RESTAGE, RC0004‐2021, PI18/00288 |
| European Commission | PI22/01469, PI19/00710 |
Keywords
- AllergoOncology
- allergy
- basophils
- cancer
- eosinophils
- granulocytes
- mast cells
- neutrophils